… for the rational introduction of HPV-16/18 vaccines into communities with and without existing
… HPV-16/18 vaccine and assess the cost-effectiveness of alternative cervical cancer control …

… DNA vaccination has emerged as a particularly promising form of therapeutic HPV vaccines
due to … This review focuses on improving the potency of therapeutic HPV vaccines through …

… Clinically relevant and ethically acceptable endpoints were important issues for the HPV
vaccine RCTs. Cervical cancer is not an ethically acceptable endpoint; it is a disease with a …

… Some important issues could impact on vaccination strategies and the deliverability of HPV
vaccines. A key question is ‘What is the duration of the protection induced by these vaccines…

… , have shown promising results in decreasing HPV infection and related diseases, such …
HPV vaccines, focusing on vaccine coverage and efficacy. In addition, pan-gender vaccination …

… oncogenic human papillomavirus (HPV) types is a necessary, but insufficient, cause in the
development of more cancers than any other virus. Currently available prophylactic vaccines …

… promoting HPV vaccine use. We developed a codebook to assist with coding HPV vaccine
… The Community Guide) strategies for increasing vaccination coverage, and other categories …

… We advocate a more independent monitoring system for vaccine immunogenicity and … with
HPV vaccination. Finally, our evaluation suggests that an expanded use of HPV vaccine into …

… Currently available prophylactic HPV vaccines are based on virus-like particles that self-…
The first HPV vaccine was licensed in 2006. All vaccines target HPV-16 and HPV-18, types …

… by HPV 6 and 11 have a lifetime risk of acquisition of 10%. HPV vaccines are subunit vaccines
… Two vaccines have been licenced since 2006/2007 and are in the National Immunisation …